Finance Operations Associate
Ascendis Pharma
Finance Operations Associate
Ascendis Pharma
Biopharmaceutical company developing long-acting prodrugs
Ascendis Pharma · Princeton, United States (Hybrid) · Temporary · Posted 2026-08-28
Salary: USD 35–45
Workplace: hybrid
Department: Finance Operations
Ascendis Pharma is a dynamic, fast-growing global biopharmaceutical company with locations in Denmark, Europe, and the United States. Today, we're advancing programs in Endocrinology Rare Disease and Oncology.
Here at Ascendis, we pride ourselves on exceptional science, visionary leadership, and skilled and passionate colleagues.
Guided by our core values of Patients, Science, and Passion, we use our TransCon® drug development platform to fulfill our mission of developing new and potentially best-in-class therapies to address unmet medical needs.
Our culture fosters a place where skilled, adaptable, and highly resourceful professionals can truly make their mark. We offer a dynamic workplace for employees to grow and develop their skills
The Finance Operations Associate is based in Princeton and reports directly to the Director, Finance Operations. Knowledge, Skills, and Experience include the following:
Key Responsibilities:
The estimated salary range for this position is $35 - $40 hourly. Actual salary determination is dependent on a variety of factors some of which include: experience, qualifications, and geographic location.
A note to recruiters:
We do not allow external search party solicitation. Presentation of candidates without written permission from the Ascendis Pharma Inc Human Resources team (specifically from: Talent Acquisition Partner or Human Resources Director) is not allowed. If this occurs your ownership of these candidates will not be acknowledged.
Benefits will be dependent on role and provided by the employer of record for this contract role.
Powered by Workable
Biopharmaceutical company developing long-acting prodrugs
Ascendis Pharma uses its TransCon technology to create long-acting prodrugs for rare endocrine diseases, with expansions into oncology and ophthalmology. The platform temporarily attaches an unmodified drug to an inert carrier and releases the active drug in a predictable, sustained way after injection, reducing how often patients must dosing. It differentiates itself through a proprietary delivery system and a track record that includes marketed therapies like SKYTROFA for pediatric growth hormone deficiency and YORVIPATH for hypoparathyroidism, along with collaborations such as a Novo Nordisk deal. The company aims to improve patient outcomes by enabling easier, less frequent dosing while expanding its pipeline across rare endocrine diseases, cancer, and eye diseases.
Explore more opportunities at Ascendis Pharma